• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email

    Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control

    Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL Commercialization



    FORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. ("Flyte") from Creatd, Inc. (OTCQB:CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator.

    The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics.

    Full Ownership, Consolidated Revenue, Immediate Cash Flow

    Flyte operates under FAA 14 CFR Part 135 certification, deploying Cirrus Vision Jets across high-frequency, short-haul regional routes where commercial airline capacity remains constrained or does not exist. The business currently generates revenue through the operation of aircraft equipped with advanced integrated safety systems, including whole-aircraft parachute technology and Safe Return™ autonomous landing capability.

    With full ownership now complete, all Flyte operations, assets, and economics are fully consolidated within VTAK, providing direct exposure to operating performance and long-term equity value creation. Going forward, Flyte's financial results will be consolidated into VTAK's financial statements.

    Strategic Impact for VTAK Shareholders

    With full ownership of Flyte, VTAK:

    • Completes a transformative business combination

    • Expands into asset-backed transportation infrastructure

    • Aligns capital, governance, and growth strategy under a single structure

    • Positions shareholders for long-term equity upside through disciplined fleet expansion

    The acquisition reflects VTAK's strategy of selectively deploying capital into operating businesses with tangible assets, scalable infrastructure, and clear paths to durable value creation.

    Inflection Point and Valuation Transformation

    "This transaction marks a defining inflection point for VTAK," said David Jenkins, CEO and Chairman of VTAK. "We have transformed from a minority investor into the owner of an operating aviation business with tangible assets, certified infrastructure, and immediate revenue. Management believes full ownership of Flyte materially enhances VTAK's long-term valuation profile by contributing consolidated revenues, asset backing, and the potential for substantial operating leverage."

    Asset-Backed Growth Platform Built for Disciplined Scale

    Unlike pre-commercial or speculative aviation concepts, Flyte operates today with:

    • Certified aircraft and trained flight crews

    • Established regulatory approvals and operating infrastructure

    • Active customer demand across multiple premium, high-volume, regional markets

    The Flyte model emphasizes capital efficiency, high aircraft utilization, and measured expansion aligned with demand and infrastructure readiness, supporting sustainable growth and long-term value creation rather than speculative deployment.

    Positioned for Regional Air Mobility - Operating Today, Optionality Tomorrow

    Flyte operates in many of the same short-haul corridors targeted by future advanced air mobility and electric aircraft developers. By operating today with certified aircraft and established infrastructure, Flyte generates real operating data, route density, and customer engagement, while maintaining flexibility to participate in future industry evolution.

    This structure allows VTAK to participate in long-term regional air mobility growth without reliance on extended certification timelines - pairing current revenue generation with future strategic optionality.

    Flyte Leadership Perspective

    "Being listed on a national stock exchange and becoming a wholly owned subsidiary of VTAK provides Flyte with aligned governance, capital support, and a clear execution framework," said Marc Sellouk, CEO and Founder of Flyte. "Our focus remains disciplined execution - operating safely, scaling responsibly, and building a durable aviation operating platform designed for long-term value creation."

    Additional Information

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company's Current Report on Form 8-K filed March 9, 2026, for additional details regarding the transaction, which is subject to customary closing conditions, including shareholder approval with respect to certain elements of the transaction.

    About Flyte

    Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel.

    Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.

    For more information, visit www.flyte.travel

    About Catheter Precision

    Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The company focuses on bringing new technologies to market through collaboration with physicians and continuous product innovation.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "focus," "intend," "plan," "potential," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "lends," "would," "may," and "could," are generally forward-looking in nature and not historical facts, including, without limitation, our belief that full ownership of Flyte materially enhances VTAK's long-term valuation profile by contributing consolidated revenues, asset backing, and the potential for substantial operating leverage and our focus remaining on disciplined execution - operating safely, scaling responsibly, and building a durable aviation operating platform designed for long-term value creation. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether because of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q's, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.

    CONTACTS:

    Investor Relations

    973-691-2000

    [email protected]

    ###



    Primary Logo

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision to Attend the Annual European Heart Rhythm Association Conference

    FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026. EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right. Davi

    4/8/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    New LockeT Data Accepted in Leading Electrophysiology Journal

    FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the manuscript titled "Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access Closure" has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a leading medical journal in the field of electrophysiology. This publication confirmed the safety and efficacy of LockeT for large-bore venous closure in 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring LBVA. These

    4/6/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/31/26 4:55:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Catheter Precision Inc.

    10-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/31/26 11:07:34 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Catheter Precision Inc.

    DEFA14A - Catheter Precision, Inc. (0001716621) (Filer)

    3/23/26 4:16:10 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care